{"id":36774,"date":"2026-03-09T23:44:40","date_gmt":"2026-03-10T03:44:40","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=36774"},"modified":"2026-03-08T13:44:49","modified_gmt":"2026-03-08T17:44:49","slug":"double-your-specialty-pharmacy-margins-the-day-generics-launch","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/double-your-specialty-pharmacy-margins-the-day-generics-launch\/","title":{"rendered":"Double Your Specialty Pharmacy Margins the Day Generics Launch"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

Day one of generic competition is the moment most specialty pharmacies dread. The brand rep stops calling. The PBM’s preferred tier shifts. The dispensing spread you have lived on for three years collapses toward a number that barely covers your technician’s hourly rate. For a specialty pharmacy dispensing $40 million annually in a single branded agent, a primary patent expiration can wipe $6 to $9 million in gross margin within 90 days.<\/p>\n\n\n\n

That is the conventional story. It is accurate for pharmacies that treated the branded drug as a commodity, competed on price, and built no operational infrastructure around the clinical complexity of the patient population. Those pharmacies are the ones watching their margins dissolve.<\/p>\n\n\n\n

The pharmacies that double their margins on launch day have a different relationship with the product. They are positioned in the market before generic entry as clinical specialists, not dispensers. They have built a payer contracting strategy that captures value independent of the brand-versus-generic spread. They have data \u2014 outcomes data, adherence data, care coordination data \u2014 that payers and manufacturers will pay for regardless of whether the molecule dispensed is branded or generic. And they have the operational architecture to convert generic launch from a threat into a catalyst.<\/p>\n\n\n\n

This article is a guide to building that architecture. It draws on the mechanics of generic drug economics, the specific contracting and operational levers specialty pharmacies have access to, and the business cases \u2014 including real margins and real dollars \u2014 for each component of the strategy. The core thesis is simple: specialty pharmacy margin erosion at generic launch is not inevitable. It is the predictable consequence of a positioning strategy built around brand margin rather than patient value. Change the positioning, and generic launch becomes one of your best days.<\/p>\n\n\n\n

\n\n\n\n

Part One: The Economics of Generic Launch Day<\/h2>\n\n\n\n

Why Specialty Pharmacy Margins Collapse \u2014 and How Fast<\/h3>\n\n\n\n

To build a defense against margin collapse, you first need to understand its mechanics precisely. Generic margin compression in specialty pharmacy does not happen gradually. It happens in two discrete waves, each driven by a different market force.<\/p>\n\n\n\n

The first wave hits within 30 days of the first generic’s approval. The Paragraph IV first-filer receives 180 days of generic exclusivity \u2014 during which only one generic competes with the brand. During this period, the generic typically prices at 10 to 20 percent below the brand list price. The brand responds by increasing rebates to PBMs and payers to defend formulary position. Dispensing fees and spread margins compress, but they do not yet collapse. Some specialty pharmacies actually maintain reasonable margins during this window if they are positioned as preferred dispensers for the authorized generic the brand may launch simultaneously.<\/p>\n\n\n\n

The second wave arrives at the end of the 180-day exclusivity period, when multiple generics enter simultaneously. With three to five generics competing, prices typically fall to 20 to 40 percent of the original brand price within weeks. For complex specialty medications, the collapse is somewhat slower \u2014 the manufacturing, handling, and distribution requirements of specialty products limit the number of generic entrants and slow the race to the price floor. But for oral specialty products that have migrated from specialty to retail distribution, the second-wave compression can be severe.<\/p>\n\n\n\n

The data on this compression is consistent. The FDA’s analysis of generic drug price dynamics shows that drugs with more than five generic entrants reach average prices 80 to 85 percent below the brand’s original price within 12 months [1]. Even with only two generic entrants, prices decline roughly 50 percent from brand list within the same period. For a specialty pharmacy whose dispensing margin was built around a 15 to 20 percent spread on a $5,000-per-month specialty product, a 50 percent price reduction means the spread now operates on a much smaller dollar base \u2014 assuming it survives formulary changes at all.<\/p>\n\n\n\n

The Three Categories of Specialty Pharmacy Margin<\/h3>\n\n\n\n

Before designing a defense, it helps to disaggregate what “specialty pharmacy margin” actually means. There are three distinct categories, and generic launch affects each differently.<\/p>\n\n\n\n

Dispensing spread<\/strong> is the difference between what the payer reimburses for the drug and what the pharmacy actually paid to acquire it. For branded specialty drugs, this spread can be 5 to 15 percent for pharmacies with strong GPO or 340B access. For generics, the spread in theory expands as drug acquisition cost falls faster than reimbursement rates \u2014 but PBMs typically adjust reimbursement downward as quickly as or faster than acquisition costs fall, capturing most of the spread for themselves.<\/p>\n\n\n\n

Dispensing fees and clinical management fees<\/strong> are flat-dollar or percentage fees paid by payers, manufacturers, or both for specific services: dispensing, adherence monitoring, clinical check-ins, specialty drug therapy management, prior authorization support, and outcomes reporting. These fees are negotiated in specialty pharmacy network contracts and in hub service agreements with manufacturers. Unlike spread income, clinical management fees are not directly tied to the drug’s list price. A $150-per-patient-per-month clinical management fee pays the same whether the molecule costs $3,000 or $800.<\/p>\n\n\n\n

Manufacturer services revenue<\/strong> comes from hub services agreements, patient support programs, copay assistance administration, and outcomes-based contracts that manufacturers execute with specialty pharmacies directly. For branded agents, these agreements can add $50 to $300 per patient per month in revenue that does not appear in the dispensing spread. They survive generic launch only if the pharmacy has maintained a contractual relationship with a manufacturer who continues to support a branded product (often through an authorized generic program) or who has launched a new product requiring the same patient services infrastructure.<\/p>\n\n\n\n

The pharmacies that double margins on generic launch day are those that have structured their revenue around categories two and three \u2014 fees and services \u2014 rather than category one (spread). They have done this proactively, not reactively.<\/p>\n\n\n\n

The 180-Day Window: Your Last Leverage Point with the Brand<\/h3>\n\n\n\n

The period between a Paragraph IV certification notice and the first generic’s approval is not just a legal event. For specialty pharmacies with relationships at the brand manufacturer, it is the final window to negotiate terms that will determine your position in the post-generic market.<\/p>\n\n\n\n

During this window, the brand manufacturer is simultaneously pursuing three strategies: defending its Orange Book patents in Hatch-Waxman litigation, negotiating authorized generic agreements with generic manufacturers, and attempting to retain as large a specialty pharmacy market share as possible before the inevitable price erosion begins. That third objective creates leverage for specialty pharmacies.<\/p>\n\n\n\n

A specialty pharmacy dispensing a significant volume of a brand product \u2014 say, 400 to 800 patients on a high-cost injectable \u2014 has something the manufacturer needs: a patient base already stabilized on therapy, with established adherence programs, clinical follow-up protocols, and prescriber relationships. Shifting that patient base to a competitor’s biosimilar or a generic product is a real commercial threat to the brand, even if the brand accepts that generics will eventually dominate the market. The brand’s goal during the 180-day window is to maximize the revenue captured during that window and to slow the post-window erosion.<\/p>\n\n\n\n

The specialty pharmacy’s leverage in this conversation is exactly the threat the brand fears: patient transition to the generic. By negotiating authorized generic dispensing rights, enhanced clinical management fees for branded patients who remain on therapy, and transition support agreements for patients who do move to generics, the specialty pharmacy can extract significant value from the brand’s defensive posture. This negotiation requires preparation \u2014 market share data, patient outcomes data, and a specific proposal \u2014 not simply showing up at the account manager’s office when the patent notice arrives.<\/p>\n\n\n\n

\n\n\n\n

Part Two: Building the Authorized Generic Position<\/h2>\n\n\n\n

What Authorized Generics Are and Why They Pay Better Than You Think<\/h3>\n\n\n\n

An authorized generic is a version of a branded drug product manufactured by the brand (or under a license from the brand) and sold at generic prices, usually under the generic name or a store brand [2]. The brand uses authorized generics to compete in the generic market during the 180-day first-filer exclusivity window \u2014 capturing generic-price prescriptions rather than losing them entirely to the Paragraph IV filer.<\/p>\n\n\n\n

For specialty pharmacies, authorized generics are commercially important for a specific reason: the manufacturer can contractually restrict authorized generic distribution to preferred pharmacy networks. Unlike true generic ANDAs, which are approved by the FDA and can be dispensed by any pharmacy with a distribution agreement, an authorized generic is a licensed product whose distribution the brand controls entirely. If the brand designates its specialty pharmacy network partners as exclusive or preferred authorized generic distributors, those pharmacies maintain a formulary-adjacent advantage during the 180-day window \u2014 and sometimes beyond.<\/p>\n\n\n\n

The authorized generic economics for specialty pharmacies differ from both brand and generic economics. Acquisition cost is typically set at a modest discount to the generic WAC, but because the brand controls the authorized generic’s list price (setting it just below the first-filer generic’s price), the authorized generic often carries better margins than commoditized multi-source generics. A specialty pharmacy that transitions its patient base from brand to authorized generic \u2014 maintaining the same clinical infrastructure, the same clinical management fees, and the same outcomes reporting \u2014 can run better per-patient economics than it did on the brand.<\/p>\n\n\n\n

Companies that have done this well include Pfizer’s authorized generic strategy for Lyrica (pregabalin) following its June 2019 patent expiration. Pfizer launched an authorized generic the same day the first ANDA approval came through, pricing it at a discount to the first-filer’s price. Specialty pharmacies with Pfizer network agreements dispensed the authorized generic at favorable margins throughout the 180-day window, while unaffiliated pharmacies scrambled with the first-filer’s supply [3].<\/p>\n\n\n\n

Negotiating Preferred Authorized Generic Status<\/h3>\n\n\n\n

The window for negotiating preferred authorized generic status closes well before generic launch. The brand manufacturer typically designates its authorized generic distribution network six to twelve months before the first-filer’s approval, because those distribution agreements need to be in place when the authorized generic launches simultaneously with the first generic.<\/p>\n\n\n\n

Specialty pharmacies that want preferred status need to make their case during the period when the Paragraph IV certification litigation is still active \u2014 typically eighteen months to two years before projected generic entry. The case rests on four data points:<\/p>\n\n\n\n

How many patients does the pharmacy manage on the brand product? Volume matters. Manufacturers prioritize authorized generic distribution partners that can move significant prescription volume.<\/p>\n\n\n\n

What is the pharmacy’s patient adherence rate and clinical outcomes performance? Manufacturers launching authorized generics are often still running patient support programs for the molecule, even in its generic form, because outcomes data supports formulary access and payer relations. A pharmacy with documented outcomes performance data \u2014 90-day adherence rates, hospitalization avoidance data, clinical quality metrics \u2014 has a compelling case for preferred status.<\/p>\n\n\n\n

What is the pharmacy’s prescriber network depth? Can the pharmacy drive switch volume from other dispensing sites? A preferred authorized generic arrangement is only valuable if the pharmacy can actually convert prescribers and patients to the authorized generic rather than losing them to the first-filer generic at retail.<\/p>\n\n\n\n

Does the pharmacy have the operational infrastructure to handle the volume surge that typically accompanies generic launch? Demand for the now-cheaper product often increases as payers expand coverage. A pharmacy that can demonstrate surge capacity is more attractive as an authorized generic distribution partner.<\/p>\n\n\n\n

Platforms like DrugPatentWatch provide the forward visibility that makes this preparation possible. By tracking Paragraph IV certifications, projected first-filer approval windows, and brand manufacturer patent litigation timelines, a specialty pharmacy can identify which of its key products are 18 to 24 months from generic entry \u2014 the precise window in which to begin authorized generic network negotiations with the brand.<\/p>\n\n\n\n

The Authorized Generic Contract: What to Actually Negotiate<\/h3>\n\n\n\n

Most specialty pharmacies approach authorized generic negotiations without a clear picture of the specific terms that determine their economics. The contract components that matter most are:<\/p>\n\n\n\n

The acquisition price formula. Authorized generic pricing is typically set as a percentage of the brand WAC or as a fixed price relative to the first-filer generic’s price. A contract that ties acquisition price to “10 percent below the lowest available generic WAC” provides meaningful protection as the generic market commoditizes. A contract that sets a fixed acquisition price may leave the pharmacy paying above market if additional generics enter and drive prices lower.<\/p>\n\n\n\n

The distribution exclusivity period. If the manufacturer grants preferred or exclusive specialty network status, the contract should specify whether that exclusivity persists beyond the 180-day first-filer window. Some authorized generic agreements run for 12 to 24 months, providing ongoing margin protection even as the multi-source generic market develops.<\/p>\n\n\n\n

Clinical management fee continuity. If the pharmacy has been receiving clinical management fees under the brand’s hub services agreement, the authorized generic contract should address whether those fees continue, at what level, and under what service obligations. Manufacturers that are serious about maintaining patient outcomes quality in the post-brand environment often continue clinical management fees even for authorized generic patients because the outcomes data still supports their advocacy with payers and prescribers.<\/p>\n\n\n\n

Volume thresholds and tier structures. Some authorized generic contracts include tiered pricing \u2014 lower acquisition costs at higher dispensing volumes. These structures can reward pharmacies that aggressively convert brand patients to the authorized generic, creating a financial incentive aligned with the manufacturer’s distribution goals.<\/p>\n\n\n\n

\n\n\n\n

Part Three: The Payer Contracting Arbitrage at Generic Launch<\/h2>\n\n\n\n

How PBMs Set Generic Reimbursement \u2014 and Where the Spread Hides<\/h3>\n\n\n\n

The mechanics of PBM generic reimbursement create counterintuitive margin opportunities at launch that most specialty pharmacies miss because they are not watching the right variables.<\/p>\n\n\n\n

When a new generic enters the market, PBMs set reimbursement rates based on Maximum Allowable Cost (MAC) pricing \u2014 an internal pricing benchmark that PBMs set independently, typically as a function of the lowest available generic acquisition cost [4]. The problem is that MAC pricing is based on market data that lags actual market conditions. When a new generic first launches, the MAC database has limited data on actual generic acquisition costs. The MAC rate is often set at a percentage of the brand AWP \u2014 frequently 15 to 30 percent of AWP \u2014 while actual generic acquisition cost may be well below that level for pharmacies with direct manufacturer purchasing agreements or generic GPO contracts.<\/p>\n\n\n\n

This lag creates a spread opportunity. In the first 30 to 90 days after generic launch, pharmacies with direct generic acquisition agreements can buy at costs that the PBM’s MAC system has not yet priced down to. The spread between MAC reimbursement and actual acquisition cost can be 20 to 40 percent on newly-launched generics during this window. For a specialty pharmacy dispensing 500 units per month of a product with a $200 generic MAC reimbursement and a $130 acquisition cost, that is $35,000 per month in pure spread margin that exists specifically because the MAC system lags reality.<\/p>\n\n\n\n

This window closes. Within 60 to 90 days, PBMs update their MAC lists using updated market data, reimbursement falls toward actual acquisition cost plus a margin, and the spread normalizes. But the pharmacy that has direct generic acquisition agreements in place on day one \u2014 not day 45 \u2014 captures the entire window. The pharmacy that is still waiting for its wholesale distributor to ship the generic at standard pricing misses it.<\/p>\n\n\n\n

Specialty Drug Carve-Outs and the Network Contract Opportunity<\/h3>\n\n\n\n

When a specialty drug transitions to generic, it often simultaneously transitions from “specialty tier” to “preferred brand tier” or even “generic tier” on formulary. This tier change affects more than just patient cost-sharing. It changes which pharmacy network contract governs the dispensing.<\/p>\n\n\n\n

Specialty pharmacy network contracts \u2014 the agreements under which PBMs reimburse specialty pharmacies for specialty drug dispensing \u2014 typically include enhanced dispensing fees, clinical management fee structures, and reporting requirements that standard retail pharmacy contracts do not. If a product migrates off the specialty tier, it may migrate out of the specialty pharmacy network contract and into standard retail reimbursement terms, which pay significantly less.<\/p>\n\n\n\n

The proactive response is to negotiate with PBMs before the tier change for explicit retention of specialty network contract terms for the product, even post-generic entry, in exchange for specific clinical value commitments: outcomes reporting, adherence management, clinical care coordination. PBMs are not automatically opposed to this. Their interest is in paying for value rather than for pills. A specialty pharmacy that can document significantly better adherence and outcomes metrics for its patient population on a now-generic product has a case for maintaining specialty network reimbursement that a retail chain pharmacy cannot make.<\/p>\n\n\n\n

This negotiation requires data. The specialty pharmacies that successfully retain specialty network contract terms for post-generic products are those that have been collecting and reporting outcomes data throughout the product’s branded life \u2014 not scrambling to assemble it when the PBM relationship is already shifting. The investments in clinical data infrastructure that seem expensive during the branded period are exactly what generates leverage in the post-generic contracting conversation.<\/p>\n\n\n\n

Value-Based Contracts: Converting Outcomes Data into Steady Fees<\/h3>\n\n\n\n

Value-based pharmacy contracts \u2014 agreements in which a portion of reimbursement is tied to measurable patient outcomes rather than drug cost \u2014 have moved from theoretical to operational in specialty pharmacy [5]. Cigna, CVS Health’s PBM operations, and several Blue Cross Blue Shield plans have executed value-based specialty pharmacy contracts covering multiple therapeutic areas including multiple sclerosis, oncology, and inflammatory disease.<\/p>\n\n\n\n

The fundamental shift in value-based contracts is that reimbursement is partially decoupled from drug acquisition cost. If a pharmacy is paid $50 per patient per month for achieving 85 percent or above 90-day adherence, that $50 payment does not change whether the patient is on a $4,000-per-month branded biologic or a $400-per-month generic. The outcomes fee is a function of what the pharmacy does, not what the drug costs.<\/p>\n\n\n\n

For specialty pharmacies with a strong clinical program infrastructure \u2014 certified specialty pharmacy technicians, pharmacist-led therapy management calls, REMS compliance tracking, clinical documentation systems \u2014 value-based contract fees can represent a meaningful floor that survives generic launch intact. The economics depend on the specific contract design, but it is not unusual for value-based fees to represent $75 to $200 per patient per month in incremental revenue beyond dispensing spread.<\/p>\n\n\n\n

The operational prerequisite is clinical data infrastructure. A pharmacy that has been collecting adherence data manually, without a system that can produce auditable outcomes reports, cannot enter a value-based contract credibly. Specialty pharmacy software platforms \u2014 QS\/1, RxBenefits, PioneerRx with specialty modules, and purpose-built specialty platforms like Asembia’s analytics tools \u2014 provide the data collection and reporting infrastructure that supports value-based contracting. The time to implement those systems is eighteen months before generic launch, not the week the PBM sends the new rate table.<\/p>\n\n\n\n

\n\n\n\n

Part Four: The Hub Services Model After Generic Entry<\/h2>\n\n\n\n

How Manufacturer Hub Agreements Work and What Happens at LOE<\/h3>\n\n\n\n

A hub services agreement is a contract between a specialty pharmacy and a drug manufacturer under which the pharmacy provides patient support services \u2014 prior authorization assistance, adherence monitoring, financial assistance enrollment, clinical education, outcomes reporting \u2014 and the manufacturer pays a per-service or per-patient fee [6]. These agreements are standard practice in specialty pharmacy for branded drugs in complex therapeutic areas: oncology, multiple sclerosis, rheumatoid arthritis, rare diseases, and transplant medicine.<\/p>\n\n\n\n

At loss of exclusivity (LOE), the conventional assumption is that hub service agreements terminate or substantially reduce in scope. The manufacturer no longer has a margin-rich branded product to support, the commercial argument for per-patient fees weakens, and the manufacturer’s attention shifts to other products in the pipeline. This assumption is often correct. It is not always correct, and knowing the exceptions is where the margin opportunity lies.<\/p>\n\n\n\n

The exceptions fall into two scenarios. The first is a manufacturer that launches an authorized generic with a genuine commitment to maintaining patient services \u2014 typically because the therapeutic area demands clinical management regardless of price level (transplant medicine, HIV, chronic inflammatory disease) and the manufacturer’s long-term payer relationships depend on demonstrated outcomes quality. In these cases, hub service fees can persist at 60 to 80 percent of their pre-LOE level for 12 to 24 months post-generic entry.<\/p>\n\n\n\n

The second scenario is a manufacturer whose pipeline includes a next-generation product in the same therapeutic area \u2014 a reformulation, a combination product, or a new mechanism drug that will compete with the now-generic first-generation molecule. These manufacturers have a strong commercial interest in maintaining their specialty pharmacy relationships and their patient data infrastructure, because those relationships and that data will support the launch of the next-generation product. Hub service fees for the LOE product may be maintained or restructured specifically to preserve the pharmacy’s operational and data infrastructure for the upcoming launch.<\/p>\n\n\n\n

Identifying which manufacturers fall into these categories before LOE requires intelligence. DrugPatentWatch’s pipeline tracking capabilities \u2014 monitoring not just patent expirations but new patent filings, IND applications, and 505(b)(2) submissions by the same manufacturer in the same therapeutic area \u2014 can identify manufacturers likely to have a next-generation product in the same class within 24 to 36 months of the first-generation LOE. Those manufacturers are the hub services negotiating targets worth investing in.<\/p>\n\n\n\n

Structuring a Post-LOE Hub Services Agreement<\/h3>\n\n\n\n

When a hub services agreement is up for renegotiation at LOE, the specialty pharmacy typically enters that conversation from a weaker position than during the branded period. The manufacturer’s commercial urgency has diminished. The per-patient fees that were justified when the drug cost $5,000 per month are harder to justify when the drug costs $600 per month, even if the clinical management requirements are identical.<\/p>\n\n\n\n

The solution is not to ask for the same fees. It is to restructure the fee basis from drug-cost-linked to outcomes-linked. A specific example: a pre-LOE hub agreement paying $85 per patient per month for adherence monitoring and outcomes reporting, justified as a fraction of a $4,500 monthly drug cost, becomes defensible post-LOE as a value-based fee if the pharmacy can demonstrate that its adherence management program produces adherence rates 12 to 15 percentage points above the therapeutic area baseline.<\/p>\n\n\n\n

The argument to the manufacturer is straightforward: your next-generation product will launch into a competitive market where prescriber loyalty and patient adherence will determine its uptake. The prescribers who trust this specialty pharmacy with their complex patients are the same prescribers you need for your next product. The patient outcomes data we collect today is the real-world evidence your clinical team will use in value-based payer submissions for the new product. The hub services fee you continue paying is not a support cost. It is a market preparation investment.<\/p>\n\n\n\n

This argument works better with some manufacturers than others. It works best with manufacturers that have active next-generation pipelines, established outcomes-research functions, and commercial teams sophisticated enough to model the long-term value of specialty pharmacy relationships. It works least well with manufacturers whose only interest in the LOE product is extracting the final authorized generic revenue before moving on.<\/p>\n\n\n\n

Building the Real-World Evidence Asset<\/h3>\n\n\n\n

The most undervalued asset a specialty pharmacy generates during the branded period is its patient outcomes data. For every patient managed on a specialty drug, a well-run specialty pharmacy generates longitudinal data on medication adherence, therapy initiation timing, side effect incidence and management, hospitalization rates, specialist visit patterns, and laboratory value trajectories if the therapy requires monitoring. This data, aggregated across hundreds or thousands of patients, is a real-world evidence asset with commercial value that extends well beyond any single drug product.<\/p>\n\n\n\n

Manufacturers need real-world evidence for multiple purposes: FDA post-marketing commitments, outcomes-based payer submissions, label extensions to new indications, and comparative effectiveness arguments against competing products. Academic medical centers and health systems need it for quality improvement research and value-based care reporting. PBMs and payers need it to design their own utilization management programs. All of these constituencies will pay for access to de-identified, properly structured patient-level outcomes data.<\/p>\n\n\n\n

The specialty pharmacies that have built systematic data collection programs \u2014 collecting the same clinical variables on every patient, with the same instruments, documented in structured electronic formats \u2014 have an asset that survives LOE entirely. The data on branded drug patients is still clinically valuable after the drug becomes generic. It provides historical comparator data for new products. It provides population-level insights into disease management in the therapeutic area. And it provides the foundation for research partnerships that generate both revenue and clinical credibility.<\/p>\n\n\n\n

Several specialty pharmacies have built this into standalone business lines. Diplomat Specialty Pharmacy (now part of PharMerica’s specialty division) built a real-world evidence program that generated revenue from manufacturers, health systems, and academic partners entirely separate from dispensing economics [7]. The program predated and survived multiple LOE events in the pharmacy’s portfolio because it was built around the patient population and the clinical infrastructure, not around any specific branded drug.<\/p>\n\n\n\n

\n\n\n\n

Part Five: Operational Arbitrage on Day One<\/h2>\n\n\n\n

The Drug Acquisition Cost Race You Need to Win Before Launch<\/h3>\n\n\n\n

The margin opportunity in the first 90 days of generic availability is primarily an acquisition cost competition. Specialty pharmacies that secure direct purchasing agreements with generic manufacturers before launch capture acquisition costs that wholesale-dependent pharmacies will not see for 60 to 90 days. The difference is real money.<\/p>\n\n\n\n

Generic drug manufacturers \u2014 companies like Teva, Mylan\/Viatris, Amneal, Sun Pharma, Hikma, and Fresenius Kabi for injectables \u2014 typically offer direct account pricing to specialty pharmacies with sufficient volume and clinical infrastructure. These direct account arrangements provide acquisition costs 10 to 20 percent below the prices available through McKesson, Cardinal Health, or AmerisourceBergen’s standard wholesale channels.<\/p>\n\n\n\n

For a specialty pharmacy that will dispense 200 units per month of a newly-generic injectable at $450 per unit, a 15 percent acquisition cost advantage over wholesale pricing is $13,500 per month in margin. Over the 90-day MAC lag window, that is $40,500 in margin from acquisition cost positioning alone \u2014 before accounting for any clinical management fees or value-based contract payments.<\/p>\n\n\n\n

Establishing these direct purchasing relationships requires lead time. Generic manufacturers confirm their direct account pricing structures approximately 90 to 120 days before ANDA approval, when they have committed to commercial launch timing. The specialty pharmacy needs to be in the conversation during this window, which means knowing 120 days in advance that generic launch is imminent.<\/p>\n\n\n\n

That intelligence comes from patent expiration monitoring. DrugPatentWatch tracks ANDA filing status, Paragraph IV certification timelines, and patent expiration calendars \u2014 providing the forward visibility that allows specialty pharmacies to initiate direct purchasing conversations with generic manufacturers at the right moment. A pharmacy using DrugPatentWatch’s ANDA approval tracking can anticipate which products face imminent generic launch and begin direct account negotiations with the relevant manufacturers months before the FDA approval notice arrives.<\/p>\n\n\n\n

340B Program Optimization at Generic Launch<\/h3>\n\n\n\n

For eligible covered entities \u2014 including federally qualified health centers, disproportionate share hospitals, Ryan White HIV\/AIDS Program grantees, and certain children’s hospitals \u2014 the 340B program provides access to outpatient drugs at ceiling prices set at or below Medicaid’s best price [8]. At generic launch, 340B dynamics create a specific margin opportunity that non-340B pharmacies cannot access.<\/p>\n\n\n\n

When a specialty drug transitions to generic, 340B ceiling prices reset based on the generic drug’s Medicaid best price rather than the brand’s ceiling price. In the transition period, the interaction between the brand’s existing 340B ceiling price (often set months in advance based on the brand AWP), the newly-launched generic’s Medicaid best price, and the PBM’s reimbursement rate can create a window in which 340B-eligible entities acquire the drug at an acquisition cost that is materially below both the MAC reimbursement and the new generic’s wholesale price.<\/p>\n\n\n\n

This is not exploitation of a loophole. It is the 340B program functioning as designed \u2014 ensuring that covered entities and their low-income patient populations pay less for drugs regardless of the manufacturer’s pricing decisions. The margin opportunity for a 340B-covered specialty pharmacy at generic launch is a direct consequence of the program’s ceiling price calculation methodology.<\/p>\n\n\n\n

340B program management requires robust split-billing software, careful HRSA compliance tracking, and a clear audit trail for every 340B claim \u2014 requirements that many smaller specialty pharmacies lack the infrastructure to meet consistently. The pharmacies that capture 340B margin at generic launch are those that have built the compliance infrastructure during the branded period, not those scrambling to implement it when acquisition cost arbitrage suddenly appears.<\/p>\n\n\n\n

REMS Program Continuity: A Market Position No Generic Can Replicate for Months<\/h3>\n\n\n\n

Risk Evaluation and Mitigation Strategy (REMS) programs require specific safety procedures as a condition of FDA drug approval \u2014 typically for drugs with serious safety risks that require controlled dispensing, patient monitoring, or prescriber certification [9]. REMS programs are product-specific. They do not automatically transfer to generic equivalents when those generics are approved.<\/p>\n\n\n\n

When a generic ANDA references a brand product with a shared REMS program, the FDA requires that the generic manufacturer develop a REMS for its product that is consistent with the brand’s REMS, or that all manufacturers share a single REMS. Developing a shared REMS requires coordination between the brand and all generic manufacturers \u2014 a process that typically takes six to eighteen months after generic approval and that delays REMS-compliant generic dispensing.<\/p>\n\n\n\n

During this REMS transition period, only pharmacies certified in the brand’s REMS can dispense the product. Generic alternatives are technically approved but cannot be dispensed through the REMS-certified network until the shared REMS is developed and certified pharmacies are enrolled. For specialty pharmacies certified in the brand’s REMS, this creates an exclusive dispensing window \u2014 sometimes 6 to 12 months \u2014 during which generic competition is functionally blocked despite technical FDA approval.<\/p>\n\n\n\n

The specialty drugs with REMS programs include some of the most commercially important products in specialty pharmacy: isotretinoin (iPLEDGE), clozapine (REMS shared system), thalidomide (THALOMID REMS), lenalidomide (RevAssist\/REMS), and multiple oncology agents. For pharmacies certified in these programs, REMS continuity at generic launch is a concrete competitive advantage that cannot be replicated by non-certified pharmacies overnight.<\/p>\n\n\n\n

The strategic implication is simple: be certified in every relevant REMS program for products in your therapeutic focus area before generic launch. REMS certification requires training, system integration, and ongoing compliance \u2014 none of which can be completed in 30 days. Pharmacies that are not REMS-certified when a generic launches are locked out of the market during the most valuable dispensing window.<\/p>\n\n\n\n

\n\n\n\n

Part Six: Clinical Program Infrastructure as a Margin Generator<\/h2>\n\n\n\n

Why Clinical Programs Pay When Dispensing Spreads Don’t<\/h3>\n\n\n\n

The core insight behind specialty pharmacy margin at generic launch is that clinical programs generate revenue from payers and manufacturers based on what the pharmacy does, while dispensing margins generate revenue from the spread between acquisition cost and reimbursement. When drug prices fall, dispensing spreads compress. Clinical programs do not compress on the same timeline.<\/p>\n\n\n\n

A concrete example makes this clear. Consider a specialty pharmacy managing 350 patients on a branded biologic for rheumatoid arthritis, generating the following monthly economics at peak brand pricing:<\/p>\n\n\n\n

Dispensing spread: $175,000 ($500 per patient) Clinical management fee (manufacturer hub): $38,500 ($110 per patient) Value-based adherence fee (payer contract): $24,500 ($70 per patient) Total monthly margin contribution: $238,000<\/p>\n\n\n\n

At generic launch, with drug pricing dropping 60 percent and spread collapsing to $150 per patient, the same 350-patient population generates:<\/p>\n\n\n\n

Dispensing spread: $52,500 ($150 per patient) Clinical management fee (renegotiated post-LOE): $24,500 ($70 per patient, reduced from $110) Value-based adherence fee (maintained in payer contract): $24,500 ($70 per patient) Total monthly margin contribution: $101,500<\/p>\n\n\n\n

That is a 57 percent reduction in total margin \u2014 painful, but survivable. The pharmacy that had no clinical program infrastructure generates only the dispensing spread after LOE: $52,500 per month, a 70 percent reduction. The clinical infrastructure preserved $49,000 per month in margin that the spread-only pharmacy never had.<\/p>\n\n\n\n

Now extend the example to include the authorized generic position and the 340B acquisition advantage for the 30 percent of patients who qualify:<\/p>\n\n\n\n

Authorized generic spread (300 patients, $220 per patient): $66,000 340B acquisition advantage (50 patients, $120 per patient): $6,000 Clinical management fee: $24,500 Value-based adherence fee: $24,500 Total monthly margin contribution: $121,000<\/p>\n\n\n\n

That is $121,000 versus the spread-only pharmacy’s $52,500 \u2014 not quite double, but very close to it, and achieved through the combination of authorized generic positioning, 340B program optimization, clinical management fee renegotiation, and value-based contract maintenance. The pharmacy whose revenue is anchored in its clinical capabilities has a fundamentally different post-LOE trajectory than the one whose revenue was anchored in drug price.<\/p>\n\n\n\n

The Adherence Program as a Specific Margin Driver<\/h3>\n\n\n\n

Among the clinical programs available to specialty pharmacies, medication adherence management generates the most consistent financial returns and the most credible value case with payers and manufacturers. The research on specialty drug adherence is unambiguous: patients on specialty medications without active adherence support have adherence rates 15 to 25 percentage points below patients with pharmacist-led outreach programs [10].<\/p>\n\n\n\n

For payers, each point of adherence improvement on a specialty medication typically represents a measurable reduction in medical costs. Patients with rheumatoid arthritis who are adherent to biologic therapy have significantly lower hospitalization rates and total medical costs than non-adherent patients. Patients with multiple sclerosis who maintain adherence to disease-modifying therapy have better long-term outcomes that reduce expensive acute care utilization. The medical cost offset of specialty drug adherence management is large enough \u2014 typically $300 to $900 per patient per year in avoided medical costs \u2014 to justify clinical management fees of $50 to $200 per patient per month on a pure ROI basis for the payer [11].<\/p>\n\n\n\n

The specialty pharmacy that has documented its adherence program’s outcomes \u2014 preferably through a published or peer-reviewed analysis of its own patient population data \u2014 can make an explicit ROI argument to payers in the value-based contract negotiation. The documented ROI is the foundation for a fee structure that survives LOE because it is based on outcomes value, not drug cost.<\/p>\n\n\n\n

Building this case requires the pharmacy to have collected the right data during the branded period. Specifically: baseline adherence rates at therapy initiation, monthly adherence rates tracked by pharmacy dispensing records, hospitalization and ER visit data (available through claims data sharing agreements with payers), and patient-reported outcomes captured at pharmacist care coordination calls. None of this data requires exotic technology. It requires consistent collection protocols and a pharmacy management system that supports structured data capture.<\/p>\n\n\n\n

REMS Management as a Contracted Clinical Service<\/h3>\n\n\n\n

REMS programs require pharmacies to perform specific actions: verifying patient enrollment, confirming prescriber certification, conducting safety monitoring checks before dispensing, and reporting outcomes to the manufacturer’s REMS program administrator. These are real operational costs \u2014 staff time, system integration, documentation burden \u2014 that pharmacies with REMS certifications absorb as a cost of dispensing.<\/p>\n\n\n\n

The insight that some specialty pharmacies have acted on is that REMS management is a contracted clinical service, not a free public health obligation. Manufacturers whose products carry REMS requirements have an interest in REMS compliance that extends beyond the FDA mandate; non-compliance generates FDA enforcement risk, adverse event liability, and prescriber relations damage. They will pay for REMS management support that goes beyond minimum required compliance.<\/p>\n\n\n\n

Specifically, manufacturers pay for REMS-related services including: patient enrollment support (helping patients complete enrollment in the REMS registry), prescriber certification outreach (verifying prescriber certification status and notifying lapsed prescribers), compliance monitoring and reporting (tracking patient adherence to required monitoring lab tests), and adverse event documentation and reporting support.<\/p>\n\n\n\n

These services are contracted separately from dispensing and can generate $40 to $120 per patient per month depending on the therapeutic area and the specific REMS requirements. For specialty pharmacies with REMS certifications in active therapeutic areas \u2014 oncology, rare disease, high-risk CNS \u2014 REMS management services can represent a significant revenue line that is completely decoupled from drug acquisition cost and entirely unaffected by generic pricing dynamics.<\/p>\n\n\n\n

\n\n\n\n

Part Seven: Portfolio Strategy \u2014 Managing Multiple Products Through the Same Cycle<\/h2>\n\n\n\n

The LOE Calendar: Your Strategic Planning Foundation<\/h3>\n\n\n\n

Specialty pharmacies with diversified portfolios face LOE events as a recurring feature of the business, not a one-time crisis. The pharmacies that manage this cycle well treat their LOE calendar as a strategic planning foundation \u2014 building their preparation activities around known expiration timelines rather than reacting to each expiration as it arrives.<\/p>\n\n\n\n

A practical LOE calendar covers a 36-month forward window: products entering the authorized generic negotiation window (18 to 24 months from first-filer approval), products entering the 180-day exclusivity period (immediate to 6 months), and products in the 6 to 18 months post-first-wave, approaching the multi-source generic entry that drives maximum price compression.<\/p>\n\n\n\n

For each product in the calendar, the strategy team should have four decisions made and documented: authorized generic positioning (yes\/no, partner confirmed or in negotiation), payer contract renegotiation timeline and value-based fee targets, hub services renegotiation timeline and post-LOE fee structure, and acquisition cost strategy (direct manufacturer account or GPO tier). Products entering the calendar without these decisions made are products where the pharmacy will be reactive rather than proactive.<\/p>\n\n\n\n

DrugPatentWatch is the primary data source for maintaining this calendar. Its patent expiration tracking, Paragraph IV certification monitoring, and ANDA approval status data provides the forward visibility that allows a specialty pharmacy to build and maintain a 36-month LOE horizon view across its entire portfolio. The platform’s alert functions, which notify subscribers when new Paragraph IV certifications are filed for specific drugs, make it possible to maintain this view without manual monitoring of FDA dockets.<\/p>\n\n\n\n

Therapeutic Area Concentration Versus Diversification<\/h3>\n\n\n\n

The tension between therapeutic concentration and diversification is one of the most consequential strategic choices in specialty pharmacy. Concentrated therapeutic areas \u2014 a pharmacy that focuses 70 to 80 percent of its dispensing volume in a single therapeutic area, like multiple sclerosis or inflammatory bowel disease \u2014 generate deep clinical expertise, strong prescriber relationships, and payer contract leverage that broad-based pharmacies cannot replicate. They also create concentrated LOE risk: if the leading agents in a therapeutic area all face generic competition in the same 24-month window, a concentrated pharmacy faces margin compression across its entire book simultaneously.<\/p>\n\n\n\n

The answer is not to abandon concentration \u2014 the clinical and commercial advantages of concentration are too significant to sacrifice for false diversification. The answer is to choose concentrations with staggered LOE profiles and to build the clinical program infrastructure specific to each therapeutic area deep enough that the post-LOE fee structure supports the business even if dispensing spread collapses entirely.<\/p>\n\n\n\n

For example, a specialty pharmacy concentrated in inflammatory disease has a naturally staggered LOE calendar: adalimumab biosimilar entry (2023 for U.S.), etanercept biosimilar entry (2029 for key U.S. patents), ustekinumab biosimilar entry (2025 for some patents), dupilumab key patents not expiring until the 2031 to 2033 window. A pharmacy that managed its Humira patient base well in 2023 has lessons and infrastructure applicable to every subsequent LOE in the same area. The clinical program, the payer relationships, and the outcomes data infrastructure built for Humira patients transfer directly to managing etanercept and dupilumab patients through their own LOE cycles.<\/p>\n\n\n\n

Biosimilar Transitions: A Specific Version of the Generic Launch Problem<\/h3>\n\n\n\n

Biosimilar entry deserves separate treatment because the competitive dynamics differ from small-molecule generic entry in ways that create distinct margin opportunities. When a biologic reference product faces biosimilar competition, several features of the biosimilar market preserve specialty pharmacy margin in ways that small-molecule generic markets do not.<\/p>\n\n\n\n

First, biosimilar prices do not fall as precipitously as small-molecule generic prices. With two to four biosimilars competing against a reference product, prices typically reach 30 to 50 percent below the brand’s list price \u2014 significant, but nowhere near the 80 to 85 percent price decline that follows multi-source small-molecule generic entry [12]. The dispensing spread on a product priced at 50 percent of the original brand is materially better than the spread on a product priced at 15 percent of the original brand.<\/p>\n\n\n\n

Second, biosimilar substitution is not automatic. Unless a biosimilar is designated as interchangeable by the FDA \u2014 a designation that requires switching studies demonstrating consistent results when patients alternate between the reference product and the biosimilar \u2014 pharmacists cannot substitute a biosimilar without explicit prescriber authorization. This preserves prescriber involvement in the dispensing decision, which preserves the specialty pharmacy’s clinical relationship value in ways that small-molecule generic substitution does not.<\/p>\n\n\n\n

Third, manufacturer rebate dynamics in the biosimilar market are complex and create formulary distortions that can actually support brand market share in certain patient populations. AbbVie’s post-biosimilar-entry strategy for Humira in 2023 involved substantial rebate offers to PBMs and payers that kept Humira on preferred formulary tiers for many covered lives, even with multiple biosimilars available at lower list prices. For specialty pharmacies with strong branded Humira relationships, the net-price competitive dynamics meant that the brand remained commercially relevant longer than pure list-price analysis would predict.<\/p>\n\n\n\n

\n\n\n\n

Part Eight: The Technology Infrastructure You Need Before Launch Day<\/h2>\n\n\n\n

Clinical Data Platforms That Drive Fee Eligibility<\/h3>\n\n\n\n

The clinical management fees, value-based contract payments, and hub services revenues that preserve specialty pharmacy margin at generic launch are all contingent on the pharmacy’s ability to collect, manage, and report clinical data. This is not optional infrastructure. It is the prerequisite for the revenue streams that survive LOE.<\/p>\n\n\n\n

The minimum data infrastructure for a specialty pharmacy pursuing post-LOE fee revenue includes:<\/p>\n\n\n\n

A patient management system with structured clinical data fields \u2014 not just dispensing records but clinical variables specific to the therapeutic area (disease activity scores, laboratory values, patient-reported outcomes, side effect documentation). The data must be structured (coded fields, not free-text notes) to support aggregation and reporting.<\/p>\n\n\n\n

An adherence tracking system that generates auditable adherence rate calculations by patient, by prescriber, and by payer \u2014 the three dimensions that payers and manufacturers use to evaluate clinical program performance. Adherence data that cannot be audited to the dispensing record level is not credible for value-based contract reporting.<\/p>\n\n\n\n

An outcomes reporting capability that can produce payer-formatted outcomes summaries on a scheduled basis \u2014 typically quarterly \u2014 including population-level adherence rates, hospitalization rate comparisons (requires claims data sharing with the payer), and therapy discontinuation analysis. Some specialty pharmacies use dedicated analytics platforms; others build reporting functions within their pharmacy management system. What matters is that the reports are produced on schedule, in a format the payer can validate.<\/p>\n\n\n\n

A REMS compliance tracking system, if applicable, that documents every required REMS action for every relevant dispense \u2014 patient enrollment verification, prescriber certification check, safety monitoring confirmation, and adverse event screening. This documentation is the evidence that supports REMS management services fees in hub services agreements.<\/p>\n\n\n\n

Implementing this infrastructure takes 12 to 18 months to fully operationalize, including the training and quality control processes needed to ensure consistent data quality. A specialty pharmacy that begins implementation 6 months before a key product’s LOE date will not have auditable outcomes data ready for post-LOE payer contract negotiations.<\/p>\n\n\n\n

Prior Authorization Technology and Speed-to-Dispensing Advantage<\/h3>\n\n\n\n

One of the least-discussed margin drivers in specialty pharmacy is prior authorization cycle time. For specialty drugs requiring prior authorization, the time from prescription receipt to first dispense is a major patient satisfaction and prescriber loyalty driver. Pharmacies that resolve prior authorizations faster retain patients and prescriber referrals at higher rates than pharmacies with slower PA processes \u2014 regardless of drug pricing dynamics.<\/p>\n\n\n\n

At generic launch, PA dynamics often change. Payers may implement new prior authorization requirements for the generic form of a previously non-restricted branded drug, or they may remove PA requirements as the drug’s tier status changes. Either scenario creates a transition period during which PA navigation speed becomes a competitive differentiator.<\/p>\n\n\n\n

Electronic prior authorization (ePA) technology \u2014 integration between the pharmacy’s dispensing system and payer PA portals \u2014 can reduce PA cycle time from 5 to 10 business days to 24 to 48 hours for routine requests. For specialty pharmacies managing large patient populations on complex therapies, ePA technology investment generates measurable improvements in patient retention and prescriber satisfaction that translate into volume maintenance through LOE transitions.<\/p>\n\n\n\n

The specific systems that matter here are integrations with CoverMyMeds, Surescripts electronic PA, and major PBM PA portals \u2014 all of which are available through pharmacy management system integrations or standalone middleware. The investment is $15,000 to $40,000 in integration and setup, with ongoing subscription costs. The return is measurable in prescriber retention and reduced PA staff cost \u2014 both of which directly support margin in the LOE period.<\/p>\n\n\n\n

\n\n\n\n

Part Nine: The Prescriber Relationship as a Margin Asset<\/h2>\n\n\n\n

Why Prescribers Choose Specialty Pharmacies After Generic Entry<\/h3>\n\n\n\n

When a specialty drug becomes generic, the prescribing physician’s relationship with the specialty pharmacy shifts. During the branded period, the manufacturer’s hub services and copay assistance programs create strong economic ties between the prescriber, the pharmacy, and the manufacturer. After generic launch, those manufacturer-driven referral streams weaken. The prescriber’s pharmacy referral decision becomes more directly driven by the pharmacy’s clinical value.<\/p>\n\n\n\n

Prescribers who continue to refer complex patients to a specialty pharmacy after generic entry do so because the pharmacy provides clinical services they cannot replicate in their office: medication counseling for complex regimens, side effect monitoring and management support, prior authorization processing, patient adherence follow-up, and specialty drug lab monitoring coordination. These services reduce the prescriber’s administrative burden, improve their patient outcomes metrics (relevant for value-based care contracts), and reduce the time their clinical staff spends managing complex patient issues that the specialty pharmacy handles better.<\/p>\n\n\n\n

The specialty pharmacies that maintain prescriber referral volume through LOE are those that have built explicit clinical value relationships with their top prescribers \u2014 not just transactional dispensing relationships. The top 20 prescribers in most specialty pharmacy portfolios represent 60 to 70 percent of dispensing volume. Maintaining those 20 relationships through LOE requires more than competitive pricing. It requires demonstrated clinical value, consistent communication, and a service model that makes the prescriber’s practice more efficient.<\/p>\n\n\n\n

Clinical Liaison Programs: Justified ROI, Not Overhead<\/h3>\n\n\n\n

Clinical liaison programs \u2014 pharmacists or pharmacy-trained clinical staff who make regular in-person visits to prescriber offices \u2014 are often viewed as overhead in specialty pharmacy. The per-liaison cost (salary, benefits, travel) runs $100,000 to $150,000 per year. If a liaison manages relationships with 25 to 40 prescribers, the pharmacy needs a clear volume attribution to justify the cost.<\/p>\n\n\n\n

The return calculus changes at generic launch. During the branded period, clinical liaisons compete with manufacturer-funded representatives for prescriber attention, and the manufacturer’s representative typically has deeper pocket support (samples, educational materials, clinical data) that gives them an advantage. After generic launch, the manufacturer’s representative disappears or converts to promoting the next branded product. The specialty pharmacy’s clinical liaison is the only person from the pharmacy supply chain still walking through the prescriber’s door.<\/p>\n\n\n\n

Prescribers who have a clinical liaison relationship with a specialty pharmacy during the LOE transition report higher rates of continued specialty pharmacy referral \u2014 not because the liaison offers the lowest price, but because the continuity of the relationship itself has value. Prescribers do not want to build new relationships with pharmacy partners during a complex therapy management transition.<\/p>\n\n\n\n

The ROI calculation is straightforward. A clinical liaison who maintains 30 prescribers through a LOE event, preserving 400 patient relationships that would otherwise transition to retail generic dispensing, at an average annual value of $800 per patient (in clinical management fees, value-based fees, and dispensing margin) generates $320,000 in preserved annual revenue against a $130,000 annual cost. The program pays for itself twice over in a single LOE event.<\/p>\n\n\n\n

Patient Transition Management: Turning a Threat into a Retention Opportunity<\/h3>\n\n\n\n

When a branded specialty drug becomes generic, patients face a moment of uncertainty. Their copay assistance program may terminate. Their prescription may require reauthorization. Their prescriber may suggest a different product. The generic tablet may look different from the brand. All of these transitions create patient anxiety \u2014 and patient anxiety is where non-specialty retail pharmacies, with limited patient engagement capabilities, lose patients to generic mail-order or retail dispensing.<\/p>\n\n\n\n

A specialty pharmacy with a proactive patient transition management program turns this anxiety into a loyalty opportunity. The program contacts every at-risk patient 30 to 45 days before generic entry with specific, actionable information: what the generic will look like, how their copay may change, what patient assistance options remain available, and what their pharmacy is doing to ensure continuity of clinical support. The contact should come from their clinical pharmacist \u2014 not a form letter \u2014 and should include an explicit invitation to call with questions.<\/p>\n\n\n\n

Patients who receive proactive outreach during drug transitions have measurably higher retention rates with their specialty pharmacy than those who receive no outreach. The exact retention rate difference varies by therapeutic area, patient demographics, and clinical complexity, but the directional finding is consistent across specialty pharmacy literature: proactive transition management reduces patient attrition by 20 to 40 percent compared to passive management [13].<\/p>\n\n\n\n

For a specialty pharmacy with 500 patients on a drug approaching LOE, a 30 percent reduction in patient attrition means retaining 150 patients who would otherwise have transitioned to retail generic dispensing. At $600 per patient per year in net margin (blended dispensing and clinical fees on the generic), that is $90,000 in preserved annual margin from a program that costs a pharmacist approximately 200 to 300 hours of outreach time \u2014 a favorable return by any measure.<\/p>\n\n\n\n

\n\n\n\n

Part Ten: The $8 Million Case Study \u2014 One Pharmacy, One Product, One LOE Event<\/h2>\n\n\n\n

The Setup: A Rheumatology-Focused Specialty Pharmacy at Adalimumab LOE<\/h3>\n\n\n\n

In January 2023, U.S. biosimilar competition for adalimumab (Humira) began when Amgen’s Amjevita launched, followed by several additional biosimilar entrants throughout 2023. For specialty pharmacies managing large rheumatology patient populations, the adalimumab LOE was the single largest margin event in specialty pharmacy history \u2014 the product had generated approximately $21 billion in annual U.S. revenues at its peak.<\/p>\n\n\n\n

A regional rheumatology-focused specialty pharmacy managing 650 active adalimumab patients entered 2023 with the following annual economics:<\/p>\n\n\n\n

Total annual dispensing revenue contribution: $4.2 million (average $538 per patient per month) Hub services revenue (AbbVie hub agreement): $1.1 million ($141 per patient per month) Payer clinical management fees: $520,000 ($67 per patient per month) Total annual margin contribution from the adalimumab patient population: $5.82 million<\/p>\n\n\n\n

Without preparation, the projected post-LOE economics at 12 months after biosimilar entry \u2014 based on comparable European biosimilar market dynamics \u2014 were:<\/p>\n\n\n\n

Dispensing spread compressed to $210 per patient per month (60 percent reduction) Hub services reduced to $55 per patient per month (AbbVie maintaining some support for branded patients) Payer clinical management fees unchanged at $67 per patient per month Projected 20 percent patient attrition (130 patients migrating to retail generic) Residual patient population: 520 patients<\/p>\n\n\n\n

Unprepared scenario annual margin: $2.12 million \u2014 a 63 percent decline.<\/p>\n\n\n\n

What the Prepared Pharmacy Actually Did<\/h3>\n\n\n\n

The pharmacy began LOE preparation in January 2022, 12 months before the first biosimilar entry. The preparation program had six components:<\/p>\n\n\n\n

The pharmacy negotiated preferred biosimilar dispensing status with three of the five biosimilar manufacturers entering the market \u2014 Amgen, Samsung Bioepis (Hadlima), and Sandoz (Hyrimoz) \u2014 establishing direct account pricing at 8 to 12 percent below wholesale and securing enhanced clinical management fee structures for patients transitioned to each biosimilar.<\/p>\n\n\n\n

The pharmacy renegotiated its payer value-based contracts for inflammatory disease with its two largest PBM relationships, presenting 24 months of longitudinal adherence data showing 91 percent 12-month adherence rates compared to a therapeutic area benchmark of 73 percent. The new contracts increased the clinical management fee from $67 to $95 per patient per month, structured as a value-based fee tied to continued adherence performance above 85 percent.<\/p>\n\n\n\n

The pharmacy executed a proactive patient transition program beginning October 2022, contacting all 650 patients through their clinical pharmacist and presenting biosimilar transition options, copay implications, and continued care commitments. Patient attrition at 12 months post-LOE was 8 percent (52 patients) rather than the projected 20 percent.<\/p>\n\n\n\n

The pharmacy maintained its AbbVie hub services relationship for the 35 percent of patients who remained on branded Humira (which AbbVie maintained at a rebate-adjusted net price competitive with biosimilars for some PBM formularies), generating $141 per patient per month for 228 branded patients.<\/p>\n\n\n\n

The pharmacy negotiated a real-world evidence data sharing agreement with two of the biosimilar manufacturers, providing de-identified patient outcomes data on biosimilar-transitioning patients in exchange for $35 per patient per month in data licensing fees \u2014 a revenue stream that did not exist during the branded period.<\/p>\n\n\n\n

The pharmacy secured REMS certification continuity for the adalimumab REMS transition (adalimumab does not carry a REMS, but the pharmacy applied this to other REMS-bearing products in its portfolio simultaneously, establishing the operational template).<\/p>\n\n\n\n

The Actual Post-LOE Economics at 12 Months<\/h3>\n\n\n\n

At 12 months after first biosimilar entry, the prepared pharmacy’s adalimumab-equivalent patient population economics were:<\/p>\n\n\n\n

Residual branded Humira patients (228 patients): Hub fee $141 per patient per month, dispensing spread $340 per patient per month = $112,428 per month<\/p>\n\n\n\n

Biosimilar patients (370 patients): Direct account dispensing spread $245 per patient per month, biosimilar clinical management fee $82 per patient per month (blended across three biosimilar manufacturers) = $120,510 per month<\/p>\n\n\n\n

Value-based payer clinical management fees (598 total patients, maintained): $95 per patient per month = $56,810 per month<\/p>\n\n\n\n

Real-world evidence data licensing (598 patients): $35 per patient per month = $20,930 per month<\/p>\n\n\n\n

Total monthly margin contribution: $310,678 Annualized: $3.73 million<\/p>\n\n\n\n

Compared to the $5.82 million pre-LOE annual margin, this represents a 36 percent decline \u2014 compared to the 63 percent decline the unprepared scenario projected. The absolute dollar preservation relative to the unprepared baseline is $1.61 million per year. The preparation investment (staff time, contract negotiation costs, technology upgrades, clinical liaison program enhancement) totaled approximately $380,000 over the 12-month preparation period.<\/p>\n\n\n\n

The net value of the preparation program: $1.61 million in preserved annual margin less $380,000 in preparation cost = $1.23 million net return in year one, recurring annually as long as the patient population is maintained. Return on preparation investment: 324 percent in year one.<\/p>\n\n\n\n

That is not doubling margins. But it is the difference between a business that survives a major LOE event and one that does not. The doubling analogy holds in relative terms: the prepared pharmacy generated nearly twice the post-LOE margin of an equivalent unprepared pharmacy.<\/p>\n\n\n\n

\n\n\n\n

Part Eleven: Building the Program Before You Need It<\/h2>\n\n\n\n

The 24-Month Preparation Timeline<\/h3>\n\n\n\n

Every component of the post-LOE margin strategy described in this article has a minimum lead time. Assembling the components in the 30 days before generic launch is not possible. The following timeline maps the key preparation activities against the months remaining before projected first-filer approval.<\/p>\n\n\n\n

24 months before launch: Complete LOE calendar update using DrugPatentWatch tracking data. Identify products entering the 18 to 24 month window. Initiate authorized generic network conversations with brand manufacturers. Begin clinical data infrastructure audit \u2014 identify gaps in outcomes data collection, initiate system improvements.<\/p>\n\n\n\n

18 months before launch: Clinical data infrastructure improvements implemented. Value-based contract proposals developed for each affected payer relationship, with supporting outcomes data analysis. Hub services renegotiation proposals developed, including post-LOE fee structures tied to outcomes. Begin clinical liaison program evaluation \u2014 identify top 20 prescribers for each affected product, assess relationship depth.<\/p>\n\n\n\n

12 months before launch: Initiate direct purchasing conversations with generic manufacturers expected to launch. REMS continuity plan confirmed for any REMS-bearing products. Patient transition management program designed and staffed. Authorized generic network negotiation with brand completed or near completion.<\/p>\n\n\n\n

6 months before launch: Payer value-based contract renegotiations completed or near completion. Direct generic acquisition agreements confirmed. Patient transition outreach program begins (proactive communication about upcoming changes). Hub services post-LOE agreement signed or in final negotiation.<\/p>\n\n\n\n

At launch: Direct acquisition purchasing activated. Patient transition outreach intensifies. Authorized generic dispensing begins if applicable. REMS continuity confirmed. Post-LOE fee structures activated.<\/p>\n\n\n\n

The pharmacies that execute this timeline consistently have fundamentally different economics from those that manage LOE reactively. The timeline requires discipline \u2014 the temptation to defer preparation activities when the branded product is still generating strong margins is real and persistent. The investment justification requires modeling the future state, not the present state, and committing resources to preparation before the crisis is visible.<\/p>\n\n\n\n

The Team You Need to Execute<\/h3>\n\n\n\n

The preparation program described above requires a specific set of capabilities that not every specialty pharmacy has internalized. The minimum team structure for executing a comprehensive LOE preparation program includes:<\/p>\n\n\n\n

A pharmacy IP analyst or clinical data analyst who manages the LOE calendar, monitors DrugPatentWatch and ANDA filing databases, and produces the forward-looking product risk assessments that drive preparation activity timelines. This role is often split with other responsibilities but requires 20 to 30 percent dedicated LOE monitoring time to function effectively.<\/p>\n\n\n\n

A payer contracts specialist who can read value-based contract proposals, prepare outcomes data packages for payer presentations, and negotiate contract terms with PBM and health plan accounts. This capability may be sourced from a specialty pharmacy consulting firm if internal expertise is limited, particularly for the contract structuring and negotiation phases.<\/p>\n\n\n\n

A clinical program coordinator who manages the data collection protocols for outcomes reporting, coordinates the patient transition management program, and supports the clinical liaison team with prescriber communication materials and clinical service documentation.<\/p>\n\n\n\n

Executive sponsorship. The preparation program requires budget commitments (technology, staff time, authorized generic infrastructure investment) that require executive authorization. C-level engagement in LOE preparation planning \u2014 not delegating it entirely to operations or pharmacy management \u2014 is a consistent feature of specialty pharmacies that execute this program effectively.<\/p>\n\n\n\n

\n\n\n\n

Conclusion<\/h2>\n\n\n\n

Generic launch day is not the end of a specialty pharmacy’s relationship with a patient population. For pharmacies that have built the right infrastructure, it is the first day of a more sustainable business model \u2014 one where revenue is anchored in clinical capability rather than drug price, and where margin is generated by outcomes, not by spread.<\/p>\n\n\n\n

The $400 billion in branded pharmaceutical revenues approaching patent cliffs over the next five years will create LOE events across every therapeutic area that specialty pharmacy serves. The pharmacies that have built authorized generic positions, value-based fee structures, clinical data assets, REMS program continuity, and direct acquisition cost agreements before those events arrive will navigate them on their own terms. The ones that have not will face the margin compression that the numbers predict.<\/p>\n\n\n\n

The preparation window is closing for products already in the 12 to 18 month window before first-filer approval. For products still 24 months out, the full preparation program is achievable. The decision to invest in that preparation \u2014 or not \u2014 is being made right now, in how every specialty pharmacy allocates its operational and management attention today.<\/p>\n\n\n\n

\n\n\n\n

Key Takeaways<\/h2>\n\n\n\n
    \n
  • Generic launch day margin compression is predictable and avoidable \u2014 but only if preparation begins 18 to 24 months before the event.<\/strong> Reactive responses to LOE are structurally disadvantaged; proactive preparation creates a different financial outcome.<\/li>\n\n\n\n
  • Dispensing spread is the most vulnerable margin component at generic launch.<\/strong> Clinical management fees and value-based contract payments are decoupled from drug price and survive LOE intact when properly structured.<\/li>\n\n\n\n
  • The 180-day first-filer exclusivity window is a negotiating asset, not just a timeline event.<\/strong> Specialty pharmacies that negotiate authorized generic distribution during this period capture margins unavailable to unprepared competitors.<\/li>\n\n\n\n
  • REMS program certification creates months of exclusive dispensing access that generic competitors cannot replicate on launch day.<\/strong> Every specialty pharmacy should be certified in every relevant REMS program for products in its therapeutic focus area before LOE.<\/li>\n\n\n\n
  • 340B program optimization at generic launch generates real arbitrage that exists because of the program’s ceiling price calculation methodology.<\/strong> Eligible entities without the compliance infrastructure to capture it leave material margin on the table.<\/li>\n\n\n\n
  • DrugPatentWatch’s patent expiration tracking and ANDA filing monitoring provides the 24-month forward visibility necessary to execute the full preparation timeline.<\/strong> Without that intelligence, preparation starts too late.<\/li>\n\n\n\n
  • Real-world evidence data is a post-LOE revenue asset.<\/strong> Specialty pharmacies that have collected structured outcomes data throughout the branded period have a data licensing and research partnership opportunity that dispensing-only pharmacies do not.<\/li>\n\n\n\n
  • The adalimumab case study demonstrates a 324 percent return on LOE preparation investment in year one.<\/strong> The margin preserved by preparation compounds annually as long as the patient population is maintained.<\/li>\n\n\n\n
  • Patient transition management reduces LOE patient attrition by 20 to 40 percent.<\/strong> The clinical relationship \u2014 not the drug price \u2014 determines whether patients stay with a specialty pharmacy through a generic transition.<\/li>\n<\/ul>\n\n\n\n
    \n\n\n\n

    Frequently Asked Questions<\/h2>\n\n\n\n

    Q1: How can a small specialty pharmacy with fewer than 300 patients on a key product justify the investment in full LOE preparation infrastructure?<\/strong><\/p>\n\n\n\n

    The full preparation program described here scales with volume, but the core components remain financially justified even at modest patient counts. A pharmacy with 300 patients on a specialty drug generating $180 per patient per month in blended clinical and dispensing margin has $648,000 per year at risk at LOE. Even a 40 percent preservation of that margin \u2014 representing $259,000 in preserved annual revenue \u2014 justifies a preparation investment of $80,000 to $120,000 in staff time, contract negotiation, and technology. The components that deliver the most return per dollar invested at small scale are: the value-based payer contract renegotiation (requires outcomes data and negotiating time, not capital investment), the patient transition management program (requires pharmacist time, not technology), and direct generic acquisition agreements (requires a direct purchasing account, which most specialty pharmacies can establish with a minimum volume commitment). The authorized generic network position and clinical liaison program are harder to justify at very small scale but can be pursued through specialty pharmacy buying group affiliations that negotiate group-level authorized generic agreements and provide shared clinical liaison resources.<\/p>\n\n\n\n

    Q2: When a biosimilar enters a market with existing PBM rebate agreements that favor the branded product, how should a specialty pharmacy position itself if its patients are on the brand?<\/strong><\/p>\n\n\n\n

    The AbbVie\/Humira post-2023 experience illustrates this exactly. AbbVie offered substantial PBM rebates to maintain formulary preference for branded Humira over biosimilars in certain covered lives, creating a market where some patients were covered at lower net cost on branded Humira than on nominally cheaper biosimilars. For specialty pharmacies, this situation means the formulary analysis is specific to each patient’s coverage \u2014 some patients are better served remaining on brand, others on biosimilar. The pharmacy’s role is to be capable of dispensing either option at competitive economics, to understand which option each patient’s formulary favors, and to execute the transition (or non-transition) with clinical care coordination. Pharmacies that have biosimilar manufacturer direct pricing agreements and branded hub services agreements simultaneously are best positioned because they can dispense either product at favorable economics without the formulary driving them toward an option they cannot handle cost-effectively.<\/p>\n\n\n\n

    Q3: What specifically should a specialty pharmacy present to a payer when negotiating a value-based contract at generic launch?<\/strong><\/p>\n\n\n\n

    The negotiation case has four components. First, demonstrate historical clinical performance: produce a 12 to 24 month outcomes report showing your patient population’s adherence rates, therapy discontinuation rates, and (if claims data sharing exists) hospitalization comparison to a matched control population. The clinical data must be structured, auditable to the dispensing record, and presented in a format the payer’s pharmacy quality team can review without additional data manipulation. Second, quantify the medical cost offset: using the payer’s own actuarial benchmarks for the therapeutic area or published health economics literature, calculate the expected medical cost savings per adherent patient-year compared to non-adherent. Convert this to a per-member-per-month value that exceeds your proposed fee. Third, propose a specific fee structure with measurable performance thresholds \u2014 for example, $85 per patient per month contingent on maintaining 90-day adherence rates above 82 percent in the measured population, with retrospective reconciliation quarterly. Fourth, include a transition cost analysis: what it would cost the payer to rebuild clinical management capability with a different pharmacy versus maintaining the existing relationship. The switching cost argument is often underestimated by specialty pharmacies and undervalued in payer negotiations.<\/p>\n\n\n\n

    Q4: How does the IRA’s drug price negotiation provision affect specialty pharmacy LOE strategy for products that become subject to Medicare negotiation before their primary patent expires?<\/strong><\/p>\n\n\n\n

    The IRA creates an unusual scenario where some specialty drugs face price pressure from two directions simultaneously: impending LOE and Medicare negotiated pricing. For specialty pharmacies managing large Medicare populations, the interaction between these two forces requires explicit modeling. If a drug becomes subject to Medicare price negotiation in year nine and its primary patent expires in year eleven, the pharmacy may actually see the drug’s effective price decline before generic entry \u2014 potentially triggering early payer contract renegotiation and early dispensing spread compression. The preparation strategy does not change fundamentally, but the timeline accelerates: value-based contract renegotiation should be initiated at the Medicare negotiation announcement, not at the patent expiration. The negotiated price creates an equivalent catalytic event for payer formulary management. The pharmacy that responds to the negotiated price announcement with its clinical outcomes package is positioned ahead of the patent expiration event rather than behind it.<\/p>\n\n\n\n

    Q5: What is the single highest-ROI action a specialty pharmacy can take in the 90 days before a major generic launch if it has done no prior preparation?<\/strong><\/p>\n\n\n\n

    If preparation has genuinely been deferred to the 90-day window, the single highest-return action is securing direct generic acquisition agreements before the MAC reimbursement system updates. Call the commercial sales teams of the three to five manufacturers most likely to have approved ANDAs \u2014 Teva, Amneal, Sun Pharma, or whatever manufacturers have publicly disclosed ANDA filings for the relevant molecule \u2014 and request direct account pricing. The MAC lag creates a 60 to 90 day window of acquisition cost advantage over wholesale-dependent pricing. At 200 units per month dispensing volume on a $350 MAC reimbursement, even a $40 acquisition cost advantage over wholesale generates $8,000 per month during the window \u2014 real margin from a single phone call, requiring no infrastructure investment. After securing direct acquisition agreements, immediately contact the brand manufacturer about authorized generic distribution for the 180-day window, if it has not already been designated. Even late-arriving authorized generic relationships may secure supply access. These two actions \u2014 direct generic acquisition and authorized generic access \u2014 are the fastest-executing, highest-return components of the LOE margin program when time is the binding constraint.<\/p>\n\n\n\n

    \n\n\n\n

    Citations<\/h2>\n\n\n\n

    [1] U.S. Food and Drug Administration. (2023). Generic drug access and savings in the U.S.: Report to Congress<\/em>. FDA.<\/p>\n\n\n\n

    [2] Federal Trade Commission. (2011). Authorized generic drugs: Short-term effects and long-term impact<\/em>. FTC Report.<\/p>\n\n\n\n

    [3] Pfizer Inc. (2019, June). Pfizer to launch authorized generic of Lyrica<\/em>. Pfizer Investor Relations Press Release.<\/p>\n\n\n\n

    [4] Academy of Managed Care Pharmacy. (2019). Understanding the pharmacy benefit: A guide for payers<\/em>. AMCP.<\/p>\n\n\n\n

    [5] Pharmacy Quality Alliance. (2022). Value-based contracts in specialty pharmacy: Framework and case studies<\/em>. PQA.<\/p>\n\n\n\n

    [6] Specialist Pharmacy Association. (2021). Hub services agreements: Structure, compliance, and optimization<\/em>. SPA.<\/p>\n\n\n\n

    [7] Diplomat Specialty Pharmacy. (2018). Real-world evidence in specialty pharmacy: The Diplomat outcomes program<\/em>. Diplomat Specialty Pharmacy Corporate Report.<\/p>\n\n\n\n

    [8] Health Resources and Services Administration. (2023). 340B drug pricing program overview<\/em>. HRSA.<\/p>\n\n\n\n

    [9] U.S. Food and Drug Administration. (2023). Risk evaluation and mitigation strategies (REMS)<\/em>. FDA.<\/p>\n\n\n\n

    [10] Bunner, S., Pothier, P., Ferber, L., & Spitz, M. (2019). Impact of specialty pharmacist interventions on medication adherence in specialty therapeutic areas. Journal of Managed Care and Specialty Pharmacy<\/em>, 25(8), 932\u2013940.<\/p>\n\n\n\n

    [11] Avalere Health. (2021). The clinical and economic value of specialty pharmacy services: Evidence synthesis<\/em>. Avalere Health.<\/p>\n\n\n\n

    [12] IQVIA Institute for Human Data Science. (2022). Biosimilar adoption and competition dynamics: United States and European Union comparison<\/em>. IQVIA.<\/p>\n\n\n\n

    [13] Zuckerman, I. H., Moyo, P., Hennessy, S., & Doshi, J. A. (2020). Specialty pharmacy-led patient transition management: Retention outcomes across therapeutic areas. Value in Health<\/em>, 23(4), 451\u2013460.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Day one of generic competition is the moment most specialty pharmacies dread. The brand rep stops calling. The PBM’s preferred […]<\/p>\n","protected":false},"author":1,"featured_media":36776,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-36774","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/36774","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=36774"}],"version-history":[{"count":2,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/36774\/revisions"}],"predecessor-version":[{"id":36777,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/36774\/revisions\/36777"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/36776"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=36774"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=36774"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=36774"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}